A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a alpha1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia.

Trial Profile

A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a alpha1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2017

At a glance

  • Drugs Silodosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Acronyms STRONG
  • Sponsors JW Pharmaceutical
  • Most Recent Events

    • 28 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top